We have further characterized this regulatory signature by identifying increased E2f5, Erg1 and Csrnp1, molecules with anti-tumor properties, and Prdm1, whose gene product BLIMP-1 is a negative regulator of interferon (IFN) beta signaling. The gene discussed is CSRNP1; the disease is neoplasm.